Heer Lab

Professor of Urology. Investigating stem cell biology and cancer.

[Heer Lab @Heer_Lab]

A Tweetorial – Does PHOTOdynamic Surgery in Non–Muscle-Invasive Bladder Cancer reduce recurrence?

[Imperial Prostate @IP_London]

🚨NEW PUBLICATION🚨
IB1-LASERCOMPLETE live in @BJUIjournal!
@TUF funded prospective feasibility study in bladder cancer:
👉 Can FCM help detrusor muscle detection in TURBT samples
📄 Read it free: https://t.co/bm6QC67jT4
Thank you to the funder, all co-authors and the patients!

[ACE (formerly HSRU) @ace_aberdeen]

Congratulations to the team at Norfolk and Norwich for reaching their ELIPSE recruitment target! 🥳🎉

@Krish_Narahari, @jonathananing, @Heer_Lab, @vishhanchanale, @benchallacombe, @BURSTurology, @NNUH

[ACE (formerly HSRU) @ace_aberdeen]

Congratulations to wonderful team at The Christie for reaching their recruitment target!!

[BURST Urology @BURSTurology]

📈#PARTIAL is now just 100 participants away from reaching its recruitment target!

🗓️We are also pleased to announce the recruitment period has been extended to 30 September 2027

Find out more about #PARTIAL here:
https://t.co/oxM4yvwkaV

[Max Diehn, MD/PhD @max_diehn]

Excited to share our new study describing uRARE-seq, a tumor-naive #LiquidBiopsy method for analyzing urine cell-free RNA (cfRNA) in #BladderCancer and other genitourinary cancers. Out today in @NatureMedicine 🧵 1/16 https://t.co/qq4IP8kQPB

[Science News @ScienceNews]

Until recently, no one had seen DNA voyaging between human cells along intercellular highways called tunneling nanotubes. https://t.co/SWBYnx7yRI

[ACE (formerly HSRU) @ace_aberdeen]

Congratulations to Liverpool for randomising their 50th participant for ELIPSE!! @Krish_Narahari, @jonathananing, @Heer_Lab, @vishhanchanale, @benchallacombe, @BURSTurology, @nhsUHLG

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

I haven’t posted much during #IBCG26, as wonderfully busy as it’s been, but I have to post this.

IMHO, the most important part of our meeting: the Patient Perspective panel.

A reminder of why we are all here. @IBCG_BladderCA @spsutkaMD @LAUrology_NL @BladderCancerUS @WorldBladderCan

[Hashim U. Ahmed @LondonProstate1]

Nice and congratulations

But, what a shame the investigators came under pressure to stop early…

Wonder who piled on the pressure?!

Should not have been terminated early as question of radical prostatectomy (& ablation) in this setting needs answering

@MarkusGraefen

[European Urology @EUplatinum]

📢 New publication in European Urology

We are pleased to highlight a new study published in European Urology, titled “Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee”.

👏 Congratulations to Valeria Panebianco, Alberto Briganti, and Witjes J.A. on this excellent contribution, together with all co-authors.

🔗 Read the full article here:
👉 https://t.co/xOxDu2vFWZ

#EuropeanUrology #Urology #UroOncology #Research #MedicalResearch #AcademicUrology

[Nature Reviews Cancer @NatureRevCancer]

NEW content online! The long return on discovery science in cancer therapeutics https://t.co/ZvNdPZhcCn

[Shilpa Gupta @shilpaonc]

Honored that our @IBCG_BladderCA
consensus paper on "Optimal management of muscle-invasive bladder cancer" has received the @EUplatinum
Impact Award as the most influential work in its June 2026 issue!

Especially meaningful to see the 🌎 impact of this work, bringing together multidisciplinary expertise to help guide evidence-based care, treatment sequencing, and the next generation of clinical trials for patients with MIBC worldwide.

Grateful to our co-authors, IBCG colleagues, and @UroDocAsh for his vision and commitment to improving bladder cancer outcomes.

Thank you @Albert0Briganti for this amazing recognition!

@CleClinicMD @CleClinicUro @caseccc

@EurUrolOncol @Uroweb @WorldBladderCan @FaltasLab @Uromigos @OncoAlert @BladderCancerUS @SpiessPhilippe @GTumors

Full paper here👇
https://t.co/96QJgYiGax

[Alexander Light @AJWLight]

Fantastic trial that will provide definitive evidence for bpMRI vs mpMRI, and fusion versus cognitive biopsy!

[Hashim U. Ahmed @LondonProstate1]

🏆Amazing achievement by the whole team and all our partners in sites across the UK.

🙏🏽Thank you all.

🔀🔀IP7-PACIFIC is a double RCT comparing prostate bpMRI to mpMRI, and visual / cognitive targeting to image fusion targeting

📶 700 to go

Funded by @CR_UK @SU2C @SU2CUK

[ProstateCancerResearch @PCR_News]

We were deeply saddened to hear of the death of broadcaster, journalist and author Edward Stourton from prostate cancer. Our thoughts are with his family, friends and colleagues at this incredibly difficult time.

We are grateful that Edward chose to speak openly about living with prostate cancer. By sharing his diagnosis in his memoir, Confessions, and speaking publicly thereafter, he helped raise awareness of the disease and encouraged more conversations about men's health.

Edward's legacy extends far beyond broadcasting. His book, Cruel Crossing, inspired many of PCR's own brilliant fundraisers who took part in our Freedom Trail Trek last year, helping them connect with the extraordinary courage of WWII refugees who crossed the Pyrenees in search of freedom, whilst raising funds to help create a better future for men with prostate cancer like Edward himself. It made the challenge even more meaningful, and we're grateful for the lasting impact his words had on our community.

[Tom Powles @tompowles1]

In this article @Annals_Oncology GLP1 receptor agonists reduce cancer incidence. The focus is on those cancers linked to obesity @AparnaKamatMD . A retrospective study with a large sample size in people looking to lose weight . A detailed case/control type method. 41%⬇️ in cancer with GLP1 injections. It’s not clear if the effects of wt loss or the agonists are having an effect. Validation needed. Great work!!

[ProstateCancerResearch @PCR_News]

PCR started investing into innovative biotechs 5 years ago, with the aim of supporting the most promising innovations to reach patients faster.

By backing these innovations early, we’re helping companies generate evidence, reach milestones and attract additional investment.

Our experience has shown that even modest, mission-driven investments can create meaningful impact for patients and the wider ecosystem. Read more about our investing experience via the following link: https://t.co/WmdfiKbQ4S

[Hashim U. Ahmed @LondonProstate1]

Not surprising - lots of extra (potentially unnecessary) ADT use for tiny glowing spots only seen on PSMA

Need to tackle the utility question - IP10-AVIDITY RCT currently strong recruitment

@IP_London @_Sam_Morris_ @Connor_Urol

[ProstateCancerResearch @PCR_News]

This week, Prostate Cancer Research, supported by the NHS, will begin sending letters to men in England who have been diagnosed with prostate cancer.

Prostate Progress is a research initiative from PCR which combines NHS health data with patients’ experiences to help researchers better understand prostate cancer and improve future care. Taking part involves completing a short online survey a few times a year and giving permission for responses to be securely linked to NHS records.

Learn more on our website:  https://t.co/XS0aafKocQ

[TheUrologyFoundation @TUF_tweets]

📢 Sharing on behalf of the @RoySocMed Urology Section:

Join the President's Address: The Privilege of Practice, The Power of Inclusion with incoming President Mr Nigel Borley.

📅 16 Oct 2026, 5pm-10pm 🔗 https://t.co/mJa0W9hAze

#Urology #MedEd